HC Wainwright reaffirmed their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN – Free Report) in a research report report published on Friday morning, Benzinga reports. The brokerage currently has a $9.00 price target on the stock.
Separately, Piper Sandler restated an overweight rating and set a $10.00 target price (down from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.
Check Out Our Latest Stock Report on ASLN
ASLAN Pharmaceuticals Stock Performance
ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report) last posted its earnings results on Friday, April 12th. The company reported ($0.78) EPS for the quarter. On average, analysts forecast that ASLAN Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.
Further Reading
- Five stocks we like better than ASLAN Pharmaceuticals
- What Are Trending Stocks? Trending Stocks Explained
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- What is a Dividend King?
- 3 Value Stocks You Can Buy Before They Become Big
- Trading Halts Explained
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.